Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2020 07:00 ET | Source: https://immatics.com/

Immatics Announces Third Quarter 2020 Financial Results and Business Update

ACTengine® IMA200 clinical trial series continues scaling globally; initial analysis for patients in ACTengine® dose escalation is on track for Q1 2021 Expansion of UTHealth partnership secures...
November 10, 2020 07:00 ET | Source: Immatics N.V.

Immatics präsentiert Phase-1-Daten der ACTolog® Multi-Target-Pilotstudie auf der 35. SITC Jahrestagung

Immatics konnte die Durchführbarkeit und Verträglichkeit seiner adoptiven Zelltherapie (ACT) IMA101 zeigen, welche körpereigene T-Zellen gegen mehrere definierte pHLA Zielstrukturen gleichzeitig...
November 10, 2020 07:00 ET | Source: https://immatics.com/

Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference

Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility, tolerability and high T-cell persistence.Clinical courses observed in patients...
October 29, 2020 07:00 ET | Source: Immatics N.V.

Immatics präsentiert präklinische Proof-of-Concept-Daten für seinen bispezifischen T-Zell-Rezeptor gegen MAGEA4/8

Präklinische Proof-of-Concept Daten für ersten bispezifischen T-Zell-Rezeptor IMA401 zeigen vollständige Remissionen transplantierter humaner Tumore in Mäusen sowie positive CMC-Eigenschaften. Die...
October 29, 2020 07:00 ET | Source: https://immatics.com/

Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8

Immatics’ first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of transplanted human tumors in mice and favorable CMC characteristics The...
September 29, 2020 07:00 ET | Source: Immatics N.V.

Immatics ernennt Arnd Christ zum Chief Financial Officer

Tübingen, Deutschland und Houston, Texas, 29. September 2020 – Immatics N.V. (NASDAQ: IMTX, „Immatics”), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-Immuntherapien für die...
September 29, 2020 07:00 ET | Source: https://immatics.com/

Immatics Appoints Arnd Christ as Chief Financial Officer

Tuebingen, Germany and Houston, Texas, September 29, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell...
September 15, 2020 07:00 ET | Source: Immatics N.V.

Immatics beruft Biotech-Experten Eliot Forster in den Aufsichtsrat

Tübingen, Deutschland und Houston, Texas, 15. September 2020 – Immatics N.V. (NASDAQ: IMTX; „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-Immuntherapien für die...
September 15, 2020 07:00 ET | Source: https://immatics.com/

Immatics Appoints Biotech Executive Eliot Forster to Board of Directors

Tuebingen, Germany and Houston, Texas, September 15, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell...
September 10, 2020 07:00 ET | Source: https://immatics.com/

Immatics Provides Update on IMA204 ACTengine® Cell Therapy Program Targeting the Tumor Microenvironment

Tuebingen, Germany and Houston, Texas, Sept. 10, 2020 (GLOBE NEWSWIRE) -- IMA204 ACTengine® cell therapy program directed at novel tumor target COL6A3 exon 6 prevalently expressed at high copy...